Generic placeholder image

Current Stem Cell Research & Therapy


ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Advances in Stem Cell Therapy for Leukemia

Author(s): Hong Tian, Qi Qu, Liming Liu and Depei Wu

Volume 11 , Issue 2 , 2016

Page: [158 - 165] Pages: 8

DOI: 10.2174/1574888X10666151019120217

Price: $65


Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective post remission treatment for leukemia, resulting in lower relapse rates than alternative therapies. However, it is limited by the lack of suitable human leukocyte antigen (HLA) matched donors and high rates of transplant-related morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT (haplo-SCT) expand the potential donor pool but are also associated with major complications. Co-infusion of third-party donor stem cellswith a CBT/haplo-SCT, which is called “dual transplantation,” has been reportedto improve the outcome of HSCTby accelerating hematopoietic reconstitution and reducing the incidence of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched donor granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cellsafter chemotherapy, the so called “microtransplantation”, has been shown to promote the graft–versus-leukemiaeffect and hasten hematopoietic recovery without amplifying GVHD. Herein, we review recent advances in stem cell therapy for leukemia with a specific focus on dual transplantation and microtransplantation.

Keywords: Allogeneic hematopoietic stem cell transplantation, cord blood, haploidentical, microtransplantation.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy